Trius to Present at November Investor Conferences
November 12, 2012 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Therapeutics to Host Analyst and Investor Update Call
November 08, 2012 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Reports 2012 Third Quarter Financial Results
November 05, 2012 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Tedizolid Safety Data Presented at IDWeek
October 19, 2012 15:30 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Oct. 19, 2012 (GLOBE NEWSWIRE) -- IDWeek 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of...
Trius Therapeutics to Present Data From Tedizolid Clinical Studies at IDWeek Conference
October 16, 2012 08:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its lead antibiotic drug candidate, tedizolid phosphate,...
Trius Therapeutics Reports Data on Broad-Spectrum Antibiotics at 52nd Annual ICAAC Meeting
September 12, 2012 12:15 ET
|
Trius Therapeutics, Inc.
SAN FRANCISCO, Sept. 12, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of...
Trius Therapeutics Announces Data Presentations on Tedizolid at 52nd Annual ICAAC Meeting
September 11, 2012 14:15 ET
|
Trius Therapeutics, Inc.
SAN FRANCISCO, Sept. 11, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of...
Trius Therapeutics to Present Data From Drug Development Programs at ICAAC
September 05, 2012 08:00 ET
|
Trius Therapeutics, Inc.
SAN FRANCISCO, Sept. 5, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its drug development programs, including...
Trius Therapeutics Secures a $25 Million Committed Equity Financing Facility With Terrapin Opportunity, L.P.
August 31, 2012 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 31, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that it has obtained a committed equity financing facility under which it may from time to time sell...
Trius to Present at September Investor Conferences
August 29, 2012 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 29, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...